Published Date: 13 Mar 2023
OSA itself predicted the incidence of MACCE in non-obese patients.
Read Full NewsFor men with intermediate-risk prostate cancer, SBRT may beat longer-course radiotherapy in some measures of quality of life, but not disease-free survival.
Weekly electronic symptom monitoring was associated with improved fatigue and physical functioning in a randomized trial of patients with metastatic breast cancer.
Outcomes improve when a novel, first-in-class immunomodulatory drug is combined with daratumumab and dexamethasone in previously treated patients.
1.
Imfinzi + Imjudo, EU approved for patients with advanced lung cancer and non-small cell lung cancer: AstraZeneca
2.
One CAR T-Cell Therapy for Multiple Myeloma Tops Another in Propensity Matched Study
3.
It has been discovered that personalized dosing in the treatment of prostate cancer improves patient outcomes.
4.
According to JAMA, 5 alpha-reductase inhibitors are not significantly linked to prostate cancer mortality.
5.
Momelotinib, a JAK inhibitor, has FDA approval to treat adult myelofibrosis in anemic patients.
1.
Emerging Advances in Hematology and Quality Improvement
2.
Practical Breakthroughs in Oncology Across Clinical Settings
3.
Nuclear Medicine's Role in Battling Women's Cancers
4.
Genetic Screening: A Game Changer in Cancer Prevention
5.
Exploring the Pleomorphic Adenoma: A Unique and Varied Tumor
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part VII
2.
An In-Depth Look At The Signs And Symptoms Of Lymphoma
3.
Signs and Symptoms of Leukemia
4.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation